MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
ADMA Biologics Operating Cycle 2011-2026 | ADMA
Annual Operating Cycle ADMA Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 391 | 336 | 393 | 495 | 566 | 600 | 533 | 191 | 220 | 323 | 339 | - | 301 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 600 | 191 | 391 |
Quarterly Operating Cycle ADMA Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 386 | 381 | 350 | - | 297 | 362 | 417 | - | 394 | 390 | 403 | - | 493 | 558 | 558 | - | 578 | 569 | 532 | - | 745 | 706 | 440 | - | 656 | 510 | 411 | 184 | 215 | 203 | 176 | - | 177 | 370 | 4.5 K | - | 1.43 K | 1.24 K | 41.7 | - | 45.5 | 64.4 | 39.7 | - | 25.6 | 23.4 | 11.2 | - | - | 20 | 21 | - | 9.9 | 15.5 | 406 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.5 K | 9.9 | 461 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alnylam Pharmaceuticals
ALNY
|
102 | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
130 | $ 0.44 | -16.64 % | $ 5.04 M |  Israel |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
178 | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
103 | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
CytomX Therapeutics
CTMX
|
12.2 | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Cue Biopharma
CUE
|
43.1 | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
120 | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
DBV Technologies S.A.
DBVT
|
71.3 | $ 20.36 | -3.32 % | $ 2.84 B |  France |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
1.89 | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
78.4 | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
321 | $ 31.37 | 1.0 % | $ 2.08 B | USA |